Injection, Trastuzumab-Anns, Biosimilar, (kanjinti), 10 Mg in Nevada

Nevada Pricing in Context

In Nevada, CPT code Q5117 (Injection, Trastuzumab-Anns, Biosimilar, (kanjinti), 10 Mg) carries an average Medicare payment of $21.58 — 0% above the national benchmark of $21.52. 37 providers across the state submitted claims for this procedure in 2023, performing 15.8K total services. Individual payments in NV ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Nevada is $161.70, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Nevada sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Codes procedures, the estimated commercial insurance price in Nevada lands near $65.34, with self-pay cash prices typically around $64.89. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.